Providence researchers conducted over 2400 studies in 2023, according to new report

May 20, 2024 Providence News Team

RENTON, Wash., May 20, 2024 – Providence researchers conducted over 2400 studies, $128M in research activities and newly enrolled over 2800 patients in clinical trials during 2023, according to a new report published by the Providence Research Network. Across the western U.S. and beyond, Providence researchers continue leading a wide range of clinical trials and other studies that are advancing care and treatments for today’s most pervasive and challenging diseases, making new treatments available to more patients, and improving health outcomes for all. 

The 2023 Providence Research Network annual report highlights some of the exemplary and life-saving work from across the Providence family of organizations, with a variety of research success stories on topics including: 

  • The evaluation of a promising immunotherapy for non-small cell lung cancer at the Providence Cancer Institute of Oregon 
  • The study of clinical factors of early-onset colon cancer at Saint John’s Cancer Institute in Southern California  
  • The expansion of a minimally invasive treatment for heart valve disease at the Swedish Heart & Vascular Institute in Washington State 
  • Multiple initiatives bringing clinical research to historically underserved communities 
  • Efforts at multiple sites to make the promise of genomic medicine accessible to more patients 

“As a community-based, Mission-driven health system with a diverse, seven-state footprint, we have a unique opportunity to make a positive impact on the communities we serve,” says Ari Robicsek, chief analytics and research officer. “The stories in this report are a few examples of the many ways Providence is delivering on that commitment and shaping the future of health care through research that reflects the diverse experiences, contexts and needs of our communities.” 

The report was released on Clinical Trials Day 2024, celebrated annually on May 20, to honor the contributions of clinical research professionals who dedicate themselves to improving health care and developing life-saving treatments.  

“We are grateful and blessed for the brilliant and dedicated minds across our organization,” adds Robicsek. “That includes all of our researchers, research coordinators, regulatory specialists, data experts and many more who are championing research to help our patients achieve optimal health outcomes today and tomorrow.” 

Download the report research

Learn more about clinical trials at Providence and how to enroll in one at the Providence Research Network website.   

About Providence 
Providence is a national, not-for-profit Catholic health system comprising a diverse family of organizations and driven by a belief that health is a human right. With 51 hospitals, more than 1,000 physician clinics, senior services, supportive housing, and many other health and educational services, the health system and its partners employ more than 120,000 caregivers serving communities across seven states – Alaska, California, Montana, New Mexico, Oregon, Texas, and Washington, with system offices in Renton, Wash., and Irvine, Calif. Learn about our vision of health for a better world at Providence.org 

About the Author

The Providence News Team brings you the updates to keep you informed about what's happening across the organizational ecosystem. From partnerships to new doctor announcements, we are committed to keeping you informed.

More Content by Providence News Team
Previous Article
With the potential to transform cancer diagnostics, Providence contributes to innovative AI-powered digital pathology model
With the potential to transform cancer diagnostics, Providence contributes to innovative AI-powered digital pathology model

A joint study between Providence, Microsoft and the University of Washington detailing work to create a nov...

Next Article
Cancer studies seek to harness the power of the immune system
Cancer studies seek to harness the power of the immune system

Explore three innovative studies targeting uveal melanoma, melanoma and head and neck squamous cell carcino...